Your browser is no longer supported. Please, upgrade your browser.
CKPT Checkpoint Therapeutics, Inc. daily Stock Chart
Checkpoint Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.16 Insider Own1.10% Shs Outstand21.20M Perf Week44.66%
Market Cap80.35M Forward P/E- EPS next Y-1.19 Insider Trans- Shs Float18.90M Perf Month46.90%
Income-27.10M PEG- EPS next Q-0.29 Inst Own2.50% Short Float0.19% Perf Quarter17.34%
Sales1.40M P/S57.39 EPS this Y3.80% Inst Trans38.74% Short Ratio0.65 Perf Half Y-17.95%
Book/sh1.17 P/B3.24 EPS next Y1.70% ROA-80.70% Target Price15.50 Perf Year-60.11%
Cash/sh1.65 P/C2.30 EPS next 5Y- ROE-102.40% 52W Range2.22 - 10.50 Perf YTD-2.32%
Dividend- P/FCF- EPS past 5Y- ROI-151.80% 52W High-63.90% Beta-
Dividend %- Quick Ratio4.80 Sales past 5Y- Gross Margin- 52W Low70.72% ATR0.39
Employees6 Current Ratio4.80 Sales Q/Q-57.10% Oper. Margin- RSI (14)68.36 Volatility23.08% 13.34%
OptionableNo Debt/Eq0.00 EPS Q/Q-78.20% Profit Margin- Rel Volume2.47 Prev Close3.73
ShortableYes LT Debt/Eq0.00 EarningsAug 08 Payout- Avg Volume56.61K Price3.79
Recom1.50 SMA2034.43% SMA5031.84% SMA200-3.04% Volume140,105 Change1.61%
Dec-08-17Initiated H.C. Wainwright Buy $11
Aug-13-18 10:30AM  CKPT: CK-101 Data Announced Zacks Small Cap Research
08:00AM  Checkpoint Therapeutics Announces Clinical Data on EGFR Inhibitor CK-101 Selected for Late-Breaking Oral Presentation at IASLC 19th World Conference on Lung Cancer GlobeNewswire
Aug-08-18 07:30AM  Checkpoint Therapeutics, Inc. (CKPT) Reports Q2 Loss, Misses Revenue Estimates Zacks -5.34%
Aug-07-18 04:30PM  Checkpoint Therapeutics Reports Second Quarter 2018 Financial Results and Recent Corporate Highlights GlobeNewswire +6.50%
Aug-02-18 10:29AM  Special Report: Biotech incubator taps investors through in-house brokerage Reuters +5.06%
Jun-28-18 10:25AM  CKPT: Checkpoint Inhibitors: Dominating the Immuno-Oncology Space Zacks Small Cap Research
Jun-04-18 08:00AM  Checkpoint Therapeutics to Participate in June Investor Conferences GlobeNewswire
May-10-18 04:30PM  Checkpoint Therapeutics Reports First Quarter 2018 Financial Results and Recent Corporate Highlights GlobeNewswire
Apr-18-18 09:00AM  Checkpoint Therapeutics Reports Preclinical Data on BET Inhibitor CK-103 at the American Association for Cancer Research Annual Meeting GlobeNewswire
Apr-05-18 08:38AM  Why Checkpoint Therapeutics (CKPT) Might Be a Diamond in the Rough Zacks
Mar-21-18 08:00AM  Checkpoint Therapeutics Initiates Dose Expansion Portion of Phase 1 Trial of Anti-PD-L1 Antibody CK-301 GlobeNewswire
Mar-19-18 07:40AM  Blog Exposure - Checkpoint Therapeutics to Present Preclinical Data on its BET Inhibitor CK-103 at AACR Meeting ACCESSWIRE
Mar-15-18 04:05PM  Checkpoint Therapeutics Reports Fourth Quarter and Full-Year 2017 Financial Results and Recent Corporate Highlights GlobeNewswire
07:30AM  Checkpoint Therapeutics Announces Preclinical Data Presentation at the 2018 American Association for Cancer Research Annual Meeting GlobeNewswire
Mar-13-18 07:45AM  Checkpoint Therapeutics to Participate in March Investor Conferences GlobeNewswire
Mar-08-18 09:00AM  Checkpoint Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock GlobeNewswire -11.99%
Mar-07-18 04:05PM  Checkpoint Therapeutics, Inc. Announces Proposed Public Offering of Common Stock GlobeNewswire
Feb-06-18 08:30AM  Checkpoint Therapeutics to Present at BIO CEO & Investor Conference GlobeNewswire
Jan-03-18 07:30AM  Checkpoint Therapeutics to Present at Biotech Showcase 2018 GlobeNewswire -6.48%
Dec-14-17 07:30AM  Checkpoint Therapeutics to Participate in LifeSci Advisors Corporate Access Event in San Francisco, January 8 10, 2018 GlobeNewswire -6.72%
Dec-08-17 10:42AM  Checkpoint Therapeutics Wins A New Bull As Company's 'Plan Is Quickly Coming Together' Benzinga +21.26%
Dec-06-17 02:20PM  CKPT: A Smokin Opportunity in PD-L1 Therapy and Beyond Zacks Small Cap Research +13.86%
Oct-05-17 09:00AM  Checkpoint Therapeutics (CKPT) Starts CK-301 Trials Zacks Small Cap Research -10.91%
07:30AM  Checkpoint Therapeutics Initiates Phase 1 Study of Anti-PD-L1 Antibody CK-301 GlobeNewswire
Sep-20-17 08:00AM  Checkpoint Therapeutics to Present at the Ladenburg Thalmann 2017 Healthcare Conference GlobeNewswire
Sep-12-17 11:00AM  Checkpoint Inhibitors Are Hot, and CKPT Has Something in the Oven Zacks Small Cap Research -5.06%
Sep-11-17 08:30AM  Checkpoint Therapeutics Receives Orphan Drug Designation for CK-101 for the Treatment of EGFR Mutation-Positive Non-Small Cell Lung Cancer GlobeNewswire
Sep-05-17 08:00AM  Checkpoint Therapeutics to Present at the 19th Annual Rodman & Renshaw Global Investment Conference GlobeNewswire
Jul-28-17 10:00AM  Checkpoint (CKPT): An Innovator of Immune-Enhanced Combination Therapies in Solid Tumors Zacks Small Cap Research
Jun-26-17 08:00AM  Checkpoint Therapeutics Commences Trading on the NASDAQ Capital Market GlobeNewswire
Feb-28-17 07:00AM  Checkpoint Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CKPT-US : February 28, 2017 Capital Cube +42.86%
Checkpoint Therapeutics, Inc., an immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's products include CK-301 in Phase I clinical trials for the treatment of non-small cell lung cancer (NSCLC); and CK-101 in the Phase 1 portion of a Phase 1/2 clinical trial for the treatment of epidermal growth factor receptor (EGFR) mutation-positive NSCLC. Its pipeline consists of glucocorticoid-induced TNFR-related protein; and carbonic anhydrase IX. The company is also developing three oral, small-molecule, targeted anti-cancer agents that inhibit epidermal growth-factor receptor mutations, the bromodomain and extra-terminal protein, and poly polymerase. Checkpoint Therapeutics, Inc. has a collaboration agreement with TG Therapeutics, Inc. to develop and commercialize the Anti-PD-L1 and Anti-GITR antibody research programs in the field of hematological malignancies. The company was founded in 2014 and is based in New York, New York. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.